Values First Advisors Inc. Takes Position in Krystal Biotech, Inc. (NASDAQ:KRYS)

Values First Advisors Inc. bought a new position in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 292 shares of the company’s stock, valued at approximately $53,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in KRYS. EFG Asset Management North America Corp. grew its holdings in Krystal Biotech by 0.5% during the 2nd quarter. EFG Asset Management North America Corp. now owns 12,555 shares of the company’s stock valued at $2,308,000 after buying an additional 60 shares in the last quarter. GAMMA Investing LLC grew its stake in Krystal Biotech by 160.3% during the second quarter. GAMMA Investing LLC now owns 151 shares of the company’s stock valued at $28,000 after acquiring an additional 93 shares in the last quarter. Nisa Investment Advisors LLC increased its holdings in Krystal Biotech by 11.1% in the 2nd quarter. Nisa Investment Advisors LLC now owns 940 shares of the company’s stock valued at $173,000 after acquiring an additional 94 shares during the last quarter. Arizona State Retirement System lifted its stake in Krystal Biotech by 2.1% in the 2nd quarter. Arizona State Retirement System now owns 5,147 shares of the company’s stock worth $945,000 after purchasing an additional 108 shares in the last quarter. Finally, Fiera Capital Corp boosted its holdings in shares of Krystal Biotech by 0.8% during the 2nd quarter. Fiera Capital Corp now owns 16,208 shares of the company’s stock valued at $2,976,000 after purchasing an additional 130 shares during the last quarter. Institutional investors own 86.29% of the company’s stock.

Insider Buying and Selling

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $197.76, for a total transaction of $4,944,000.00. Following the completion of the sale, the insider now directly owns 1,500,882 shares of the company’s stock, valued at $296,814,424.32. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 14.10% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on the company. William Blair upgraded Krystal Biotech to a “strong-buy” rating in a research report on Friday, August 30th. Chardan Capital boosted their price target on shares of Krystal Biotech from $153.00 to $208.00 and gave the stock a “buy” rating in a research report on Monday, August 5th. Stifel Nicolaus upped their price target on shares of Krystal Biotech from $204.00 to $220.00 and gave the company a “buy” rating in a research note on Wednesday, September 11th. HC Wainwright lifted their price objective on shares of Krystal Biotech from $200.00 to $221.00 and gave the stock a “buy” rating in a research note on Wednesday, August 28th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Krystal Biotech in a report on Thursday, August 29th. One investment analyst has rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $196.75.

Krystal Biotech Stock Up 0.3 %

KRYS stock opened at $175.51 on Friday. Krystal Biotech, Inc. has a twelve month low of $93.95 and a twelve month high of $219.34. The firm has a market cap of $5.04 billion, a price-to-earnings ratio of 48.09 and a beta of 0.82. The business’s fifty day simple moving average is $185.29 and its two-hundred day simple moving average is $179.94.

Krystal Biotech (NASDAQ:KRYS) last released its quarterly earnings data on Monday, August 5th. The company reported $0.53 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.50 by $0.03. The company had revenue of $70.28 million during the quarter, compared to analysts’ expectations of $65.27 million. Krystal Biotech had a net margin of 63.73% and a return on equity of 1.99%. The firm’s quarterly revenue was up 70283900.0% on a year-over-year basis. During the same period in the previous year, the company earned ($1.25) EPS. Research analysts expect that Krystal Biotech, Inc. will post 3.13 EPS for the current year.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).